Lisdexamfetamine Dimesylate Oral Solution for ADHD to Be Available Mid-2026

 ADHD in the News 2026-02-12


Azurity Pharmaceuticals has announced that lisdexamfetamine dimesylate (Arynta) oral solution will be available mid-2026 for treating attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older.1 Arynta gained US Food and Drug Administration approval back on June 16, 2025, for the treatment of ADHD in adults and pediatric patients 6 years and older, and moderate to severe binge eating disorder in adults.2

View Article: Psychiatric Times, February 11, 2026




Other Articles in this Edition

Psychologists underserve adults with ADHD

ADHD Identified as Causal Risk Factor for Coronary Artery Disease and Heart Failure

ADHD Symptoms Predict Distinct Creative Problem-Solving Styles and Superior Solving Ability

My 11-year-old treats our house like a personal gymnasium. I’m at my wit’s end.

When ADHD is talked about as a fad – it does more than misrepresent science (Opinion)

Neurodivergent youth in the U.S. are at increased risk for dating abuse, according to study

Severe teen ADHD symptoms predict lower income and higher arrest rates by age 40

ADHD Women Face More Perimenopausal Symptoms

Aldo Conti, PhD, says trigeminal nerve stimulation ineffective for pediatric ADHD

Journal Digest: GLP-1s, Co-Occurring Borderline and ADHD, and More

Private: Evening Chronotypes and Circadian Dysregulation Prevalent in Adult ADHD

Otsuka awareness campaign urges HCPs to see ‘All of ADHD’

Lisdexamfetamine Dimesylate Oral Solution for ADHD to Be Available Mid-2026

Alton Towers U-turns on plan to restrict disability pass